CERE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CERE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-06-08), Cerevel Therapeutics Holdings's share price is $40.02. Cerevel Therapeutics Holdings's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.16. Hence, Cerevel Therapeutics Holdings's Price-to-Operating-Cash-Flow Ratio for today is .
The historical rank and industry rank for Cerevel Therapeutics Holdings's Price-to-Operating-Cash-Flow or its related term are showing as below:
Cerevel Therapeutics Holdings's Cash Flow from Operations per share for the three months ended in Mar. 2024 was $-0.66. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.16.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -9.70% per year.
During the past 5 years, Cerevel Therapeutics Holdings's highest 3-Year average Operating Cash Flow per Share Growth Rate was -9.70% per year. The lowest was -51.60% per year. And the median was -30.65% per year.
The historical data trend for Cerevel Therapeutics Holdings's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cerevel Therapeutics Holdings Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
Price-to-Operating-Cash-Flow | - | - | - | - | - |
Cerevel Therapeutics Holdings Quarterly Data | ||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Price-to-Operating-Cash-Flow | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Cerevel Therapeutics Holdings's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Cerevel Therapeutics Holdings's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Cerevel Therapeutics Holdings's Price-to-Operating-Cash-Flow falls into.
Cerevel Therapeutics Holdings's Price-to-Operating-Cash-Flow ratio for today is calculated as
Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
= | 40.02 | / | -2.162 | |
= |
Cerevel Therapeutics Holdings's Share Price of today is $40.02.
Cerevel Therapeutics Holdings's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.16.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
Price-to-Operating-Cash-Flow Ratio | = | Market Cap | / | Cash Flow from Operations |
Thank you for viewing the detailed overview of Cerevel Therapeutics Holdings's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
N Anthony Coles | director, officer: See Remarks | MORRIS CORP. CENTER I; BLDG. B; 4TH FLR., 300 INTERPACE PARKWAY, PARSIPPANY NJ 07054 |
Ramiro Sanchez | officer: Chief Medical Officer | C/O CEREVELL THERAPEUTICS HOLDINGS INC., 131 DARTMOUTH STREET SUITE 502, BOSTON MA 02116 |
Kenneth Dipietro | officer: Chief Human Resources Officer | C/O BIOGEN IDEC INC., 133 BOSTON POST ROAD, WESTON MA 02493 |
Susan Altschuller | officer: Chief Financial Officer | 45 TENNYSON ST., SOMERVILLE MA 02145 |
Mark Bodenrader | officer: See Remarks | C/O CEREVEL THERAPEUTICS HOLDINGS INC., 131 DARTMOUTH STREET SUITE 502, BOSTON MA 02116 |
Kathleen Tregoning | officer: See Remarks | C/O CEREVEL THERAPEUTICS HOLDINGS, INC., 131 DARTMOUTH STREET SUITE 502, BOSTON MA 02116 |
Scott Akamine | officer: Chief Legal Officer | C/O AEON BIOPHARMA, INC., 4040 MACARTHUR BLVD., SUITE 260, NEWPORT BEACH CA 92660 |
Deval L Patrick | director | BAIN CAPITAL, LLC, 200 CLARENDON STREET, BOSTON MA 02116 |
Adam Koppel | director | C/O BROOKSIDE CAPITAL, LLC, JOHN HANCOCK TOWER, 200 CLARENDON ST, BOSTON MA 02116 |
Perceptive Life Sciences Master Fund Ltd | director | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Christopher R Gordon | director | C/O BAIN CAPITAL, LLC, JOHN HANCOCK TOWER, 200 CLARENDON STREET, BOSTON MA 02116 |
Bain Capital Investors Llc | 10 percent owner | 200 CLARENDON STREET, BOSTON MA 02116 |
Paul D. Burgess | officer: See Remarks | C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421 |
Renaud Ronald C Jr | director, officer: President & CEO | C/O IDENIX PHARMACEUTICALS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE MA 02109 |
Marijn E Dekkers | director | GENERAL ELECTRIC COMPANY, 41 FARNSWORTH STREET, BOSTON MA 02210 |
From GuruFocus
By Business Wire • 01-08-2024
By Marketwired • 10-11-2023
By PRNewswire • 01-03-2024
By PRNewswire • 12-07-2023
By PRNewswire • 12-19-2023
By GuruFocus Research • 12-23-2023
By GuruFocus Research • 12-29-2023
By PRNewswire • 12-07-2023
By PRNewswire • 12-09-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.